These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27739357)

  • 61. Synthesis and biological evaluation of flexible and conformationally constrained LpxC inhibitors.
    Löppenberg M; Müller H; Pulina C; Oddo A; Teese M; Jose J; Holl R
    Org Biomol Chem; 2013 Sep; 11(36):6056-70. PubMed ID: 23917427
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety.
    Cohen F; Aggen JB; Andrews LD; Assar Z; Boggs J; Choi T; Dozzo P; Easterday AN; Haglund CM; Hildebrandt DJ; Holt MC; Joly K; Jubb A; Kamal Z; Kane TR; Konradi AW; Krause KM; Linsell MS; Machajewski TD; Miroshnikova O; Moser HE; Nieto V; Phan T; Plato C; Serio AW; Seroogy J; Shakhmin A; Stein AJ; Sun AD; Sviridov S; Wang Z; Wlasichuk K; Yang W; Zhou X; Zhu H; Cirz RT
    ChemMedChem; 2019 Aug; 14(16):1560-1572. PubMed ID: 31283109
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fluorescence-based methods to assay inhibitors of lipopolysaccharide synthesis.
    Hernick M
    Methods Mol Biol; 2011; 739():123-33. PubMed ID: 21567323
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.
    Yamada Y; Takashima H; Walmsley DL; Ushiyama F; Matsuda Y; Kanazawa H; Yamaguchi-Sasaki T; Tanaka-Yamamoto N; Yamagishi J; Kurimoto-Tsuruta R; Ogata Y; Ohtake N; Angove H; Baker L; Harris R; Macias A; Robertson A; Surgenor A; Watanabe H; Nakano K; Mima M; Iwamoto K; Okada A; Takata I; Hitaka K; Tanaka A; Fujita K; Sugiyama H; Hubbard RE
    J Med Chem; 2020 Dec; 63(23):14805-14820. PubMed ID: 33210531
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Scalable Synthesis of the Difluoromethyl-allo-threonyl Hydroxamate-Based LpxC Inhibitor LPC-058.
    Liang X; Gopalaswamy R; Navas F; Toone EJ; Zhou P
    J Org Chem; 2016 May; 81(10):4393-8. PubMed ID: 27128325
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties.
    Pirrung MC; Tumey LN; McClerren AL; Raetz CR
    J Am Chem Soc; 2003 Feb; 125(6):1575-86. PubMed ID: 12568618
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Complex Structure of Protein AaLpxC from
    Fan S; Li D; Yan M; Feng X; Lv G; Wu G; Jin Y; Wang Y; Yang Z
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33800069
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Site-directed mutagenesis of the bacterial metalloamidase UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC). Identification of the zinc binding site.
    Jackman JE; Raetz CR; Fierke CA
    Biochemistry; 2001 Jan; 40(2):514-23. PubMed ID: 11148046
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Para-(benzoyl)-phenylalanine as a potential inhibitor against LpxC of Leptospira spp.: homology modeling, docking, and molecular dynamics study.
    Pradhan D; Priyadarshini V; Munikumar M; Swargam S; Umamaheswari A; Bitla A
    J Biomol Struct Dyn; 2014; 32(2):171-85. PubMed ID: 23383626
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies.
    Kalinin DV; Agoglitta O; Van de Vyver H; Melesina J; Wagner S; Riemann B; Schäfers M; Sippl W; Löffler B; Holl R
    Bioorg Med Chem; 2019 May; 27(10):1997-2018. PubMed ID: 30954331
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Synthesis, biological evaluation, and molecular docking studies of aldotetronic acid-based LpxC inhibitors.
    Wimmer S; Hoff K; Martin B; Grewer M; Denni L; Lascorz Massanet R; Raimondi MV; Bülbül EF; Melesina J; Hotop SK; Haupenthal J; Rohde H; Heisig P; Hirsch AKH; Brönstrup M; Sippl W; Holl R
    Bioorg Chem; 2023 Feb; 131():106331. PubMed ID: 36587505
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Active site metal ion in UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) switches between Fe(II) and Zn(II) depending on cellular conditions.
    Gattis SG; Hernick M; Fierke CA
    J Biol Chem; 2010 Oct; 285(44):33788-96. PubMed ID: 20709752
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Common and varied molecular responses of Escherichia coli to five different inhibitors of the lipopolysaccharide biosynthetic enzyme LpxC.
    Möller AM; Vázquez-Hernández M; Kutscher B; Brysch R; Brückner S; Marino EC; Kleetz J; Senges CHR; Schäkermann S; Bandow JE; Narberhaus F
    J Biol Chem; 2024 Apr; 300(4):107143. PubMed ID: 38458396
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Amphipathic benzoic acid derivatives: synthesis and binding in the hydrophobic tunnel of the zinc deacetylase LpxC.
    Shin H; Gennadios HA; Whittington DA; Christianson DW
    Bioorg Med Chem; 2007 Apr; 15(7):2617-23. PubMed ID: 17296300
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synthesis and biological evaluation of triazolyl-substituted benzyloxyacetohydroxamic acids as LpxC inhibitors.
    Hoff K; Mielniczuk S; Agoglitta O; Iorio MT; Caldara M; Bülbül EF; Melesina J; Sippl W; Holl R
    Bioorg Med Chem; 2020 Jul; 28(13):115529. PubMed ID: 32386952
    [TBL] [Abstract][Full Text] [Related]  

  • 76. TP0586532, a non-hydroxamate LpxC inhibitor, reduces LPS release and IL-6 production both in vitro and in vivo.
    Fujita K; Takata I; Yoshida I; Takashima H; Sugiyama H
    J Antibiot (Tokyo); 2022 Mar; 75(3):136-145. PubMed ID: 34987187
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Metalloenzyme inhibitors for the treatment of Gram-negative bacterial infections: a patent review (2009-2012).
    Supuran CT; Carta F; Scozzafava A
    Expert Opin Ther Pat; 2013 Jul; 23(7):777-88. PubMed ID: 23458841
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antibacterial activity of xylose-derived LpxC inhibitors - Synthesis, biological evaluation and molecular docking studies.
    Dreger A; Hoff K; Agoglitta O; Hotop SK; Brönstrup M; Heisig P; Kirchmair J; Holl R
    Bioorg Chem; 2021 Feb; 107():104603. PubMed ID: 33429229
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
    Piizzi G; Parker DT; Peng Y; Dobler M; Patnaik A; Wattanasin S; Liu E; Lenoir F; Nunez J; Kerrigan J; McKenney D; Osborne C; Yu D; Lanieri L; Bojkovic J; Dzink-Fox J; Lilly MD; Sprague ER; Lu Y; Wang H; Ranjitkar S; Xie L; Wang B; Glick M; Hamann LG; Tommasi R; Yang X; Dean CR
    J Med Chem; 2017 Jun; 60(12):5002-5014. PubMed ID: 28549219
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chiral pool synthesis and biological evaluation of C-furanosidic and acyclic LpxC inhibitors.
    Müller H; Gabrielli V; Agoglitta O; Holl R
    Eur J Med Chem; 2016 Mar; 110():340-75. PubMed ID: 26866455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.